Q2 2016 Conference Call - morphosys.de€¦ · MOR208 ASCO Update Phase 2a in R/R NHL Long Duration...

Q2 2016

Conference Call

August 1, 2016

1© MorphoSys - Q2 2016 Conference Call

Today on the Call

© MorphoSys - Q2 2016 Conference Call

Simon Moroney

CEO

Jens Holstein

CFO

Claudia Gutjahr-Löser

Head of Corporate

Communications & IR

2

Safe Harbour


This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to

various risk factors and uncertainties including changes in business, economic competitive conditions,

regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company’s Annual Report.

3

MOR208 ASCO Update Phase 2a in R/R NHL

Long Duration of Responses

* Includes follicular lymphoma and other indolent NHLs. One patient with stable disease had a late response (PR) after

17 months in follow-up. This patient is not shown in the figure.


Jurczak et al., Abstract #7545, ASCO 2016

Long-lasting responses,

up to >26 months

PFS rate:

>40% at 12 months

CR, complete response; DLBCL, diffuse large B-cell lymphoma;

NHL, non-Hodgkin’s lymphoma; PR, partial response

4

MOR208

Comprehensive Clinical Development Plan


Indication 2016 2017 2018

NHL

DLBCL

CLL

Phase 2

Phase 2/3

IIT: Investigator-initiated trial

L-MIND: MOR208 (12mg/kg) + lenalidomide; 2nd line R/R; N=80

B-MIND: Safety evaluation expected to start soon leading into anticipated

pivotal study in 2017 to compare MOR208 (12 mg/kg) + bendamustine vs.

rituximab + bendamustine; 2nd line R/R; N~330

COSMOS: MOR208 (12mg/kg) + combo partner; BTKi-failures

MOR208 (9mg/kg) + lenalidomide; R/R, naive & Richter’s Transformation

MOR208 + ibrutinib in ibrutinib failures

MOR208

(12 mg/kg); N=92

} N=80 (Ohio State Univ. IIT)

5

MOR202

A Differentiated Antibody for Multiple Myeloma

© MorphoSys - Q2 2016 Conference Call 6

Phase 1/2a study in r/r MM – final dosing cohorts underway

MOR202 (16mg/kg)

MOR202 (16mg/kg) + Len/Dex

MOR202 (16mg/kg) + Pom/Dex

Updated data presented at ASCO 2016

Very short 2-hour infusion time with

IRRs (grades 1 & 2) in only 14% of pts.

Good responses in combo with IMiDs

2 CRs in 4 patients who were

treated per protocol in 8mg/kg

MOR202 + Pom/Dex (3rd line)

2 PRs, 1 VGPR (out of 4) in 8mg/kg

MOR202 + Len/Dex

Responses further deepening under ongoing treatment

The MOR Portfolio

5 Clinical Product Candidates, 14 Total


Program Indication Target Discovery Preclinic Phase 1 Phase 2 Phase 3

Unpartnered

MOR208 DLBCLCD19

CLL

MOR202 Multiple myeloma CD38

MOR107 Fibrosis AT2-R

Immuno-oncology program

CancerMHC-associated peptides

6 Programs Various Various

Co-development & co-promotion

MOR209/ES414 (Emergent)

Prostate cancer PSMA / CD3

MOR106(Galapagos)

Inflammation Undisclosed

Immuno-oncology program(Merck Serono)

Cancer Undisclosed

Outlicensed to GSK

MOR103/GSK3196165

RA

GM-CSFOsteoarthritis of the hand

FTD, orphan status US & EU

Orphan status US & EU

Strategic Long-Term Oncology Alliance

with MD Anderson Cancer Center


Joint identification, validation and development of novel anti-

cancer antibodies through to clinical proof-of-concept

Working on numerous targets in a variety of indications, using

MorphoSys‘s Ylanthia platform

Conducting early clinical studies

MorphoSys with option to develop antibodies in later clinical

stages in its proprietary pipeline

Complementing the parties’ drug discovery and clinical strengths, the partnership is intended to

provide access to novel targets in oncology broadening MorphoSys‘s proprietary development pipeline.

8


The MorphoSys Pipeline

27 Clinical Product Candidates, 104 Total

Program/Partner Target Disease Area Discovery Preclinic Phase 1 Phase 2 Phase 3

Guselkumab (CNTO1959), Janssen IL23p19 Psoriasis

Gantenerumab, Roche Amyloid-ß Alzheimer’s disease

MOR208 CD19 ALL, CLL, NHL

MOR202 CD38 Multiple myeloma

MOR103/GSK3196165, GSK GM-CSF Inflammation

Anetumab Ravtansine (BAY94-9343), Bayer Mesothelin (ADC) Solid tumors

Bimagrumab (BYM338), Novartis ActRIIB Musculoskeletal diseases

BHQ880, Novartis DKK-1 Multiple myeloma

BPS804, Mereo/Novartis Sclerostin Brittle bone syndrome

CNTO3157, Janssen - Inflammation

CNTO6785, Janssen - Inflammation

Elgemtumab (LJM716), Novartis HER3 Cancer

Tarextumab (OMP-59R5), OncoMed Notch 2 Solid tumors

Tesidolumab (LFG316), Novartis C5 Eye diseases

VAY736, Novartis BAFF-R Inflammation

Utomilumab (PF-05082566), Pfizer 4-1BB Solid tumors

MOR209/ES414, Emergent PSMA/CD3 Prostate cancer

MOR106, Galapagos - Inflammation

BAY1093884, Bayer TFPI Hemophilia

BI–836845, BI IGF-1 Solid tumors

NOV-7, Novartis - Eye diseases

NOV-8, Novartis - Inflammation

NOV-9, Novartis - Diabetic eye diseases

NOV-10, Novartis - Cancer

NOV-11, Novartis - Blood disorders

NOV-12, Novartis - Prevention of thrombosis

Vantictumab (OMP-18R5), OncoMed Fzd 7 Solid tumors

MOR107 (LP2) AT2-R Fibrosis

Immuno-oncology program, Immatics - Cancer

Immuno-oncology program, Merck - Cancer

6 MOR programs - Various

90 Partnered Discovery Programs

13 MOR Programs

1 Outlicensed Program

Most advanced development stage

In addition, 23 partnered programs in preclinic, and 45 partnered programs in discovery

Income Statement


in EUR million* 6-Months 2016 6-Months 2015

Revenues 24.3 82.6

Operating Expenses

Research and Development# 36.7 33.9

General and Administrative 6.9 7.0

Total Operating Expenses 43.5 40.9

Other Income/(Expenses) 0.1 4.4

Earnings before Interest and Taxes (EBIT) (19.2) 46.1

Finance Income/(Expenses) 0.4 1.9

Income Tax Income/(Expenses) 0.02 (11.4)

Consolidated Net Profit/(Loss) (18.8) 36.5

Diluted Net Profit/(Loss) per Share (in EUR) (0.72) 1.39

* Differences due to rounding

# Split of R&D Expenses, in EUR million 6-Months 2016 6-Months 2015

Proprietary R&D Expenses (incl. Technology Development) 28.3 25.3

Partnered Discovery Expenses 8.4 8.6

Segment Reporting


in EUR million* 6-Months 2016 6-Months 2015

Proprietary Development

Segment Revenues 0.3 59.6

Operating Expenses 28.3 24.0

Segment EBIT (27.8) 40.2

Partnered Discovery

Segment Revenues 23.9 23.0

Operating Expenses 8.8 10.6

Segment EBIT 15.1 12.5

11


Balance Sheet


in EUR million* Jun 30, 2016 Dec 31, 2015

Assets

Cash, Cash Equivalents# 67.6 90.9

Available-for-sale Financial Assets# 66.2 64.3

Bonds, Available-for-sale# 27.0 33.1

Financial Assets Classified as Loans and Receivables# 64.4 94.6

Other Current Assets 17.4 17.2

Financial Assets Classified as Loans and Receivables,

Net of Current Portion# 54.5 15.5

Other Non-current Assets 83.5 84.5

Total Assets 380.6 400.1

Liabilities & Stockholders’ Equity

Total Current Liabilities 28.9 27.5

Total Non-current Liabilities 9.2 9.9

Total Stockholders’ Equity 342.5 362.7

Total Liabilities & Stockholders’ Equity 380.6 400.1

# As of 06/30/2016, MorphoSys’s liquidity position amounted to €279.7 million (12/31/2015: €298.4 million).

12


Financial Guidance 2016 Re-confirmed


in EUR million* Guidance 2016

Group Revenues 47 to 52

Proprietary R&D Expenses

(incl. Technology Development)76 to 83

EBIT -58 to -68

13

Q&A Session

Q2 2016 Conference Call


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® , Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered

trademarks of the MorphoSys Group.

Thank You

www.morphosys.com

Corporate Communications & Investor Relations

Phone +49 (0)89 / 899 27-404

Fax +49 (0)89 / 899 27-5404

Twitter @MorphoSys

Email [email protected]

Date post:	16-Jun-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

Q2 2016 Conference Call - morphosys.de€¦ · MOR208 ASCO Update Phase 2a in R/R NHL Long Duration...

Documents